The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

MRI as a means of screening for prostate cancer? Probably not!

A report on the HealthDay web site related to a presentation about the role of MRI scanning in the diagnosis of localized prostate cancer seems to demonstrate a significant division of views about the value of standardized use of mpMRI in the diagnosis of prostate cancer. … READ MORE …

Serial mpMRIs instead of serial biopsies for men on active surveillance

The role of baseline and repeat multiparametric MRI (mpMRI) scanning as a substitute for repeat biopsies in the initial evaluation and ongoing management of men on active surveillance continues to evolve. … READ MORE …

The evolving role of MRI imaging in undiagnosed prostate cancer

As we have been pointing out for a while, the actual and potential roles for the use of multiparametric MRI (mpMRI) scanning in the diagnosis of prostate cancer is changing, and quite fast too. … READ MORE …

The role of 3 T mpMRI in monitoring men on active surveillance

A newly published paper in the American Journal of Roetgenology provides an early data set on the application of 3 T multiparameric MRI scans in monitoring men on active surveillance (as opposed to the use of serial biopsies). … READ MORE …

PROMIS study endorses mpMRI prior to prostate biopsy for many patients

The PROMIS study is a UK-based study designed to confirm earlier data suggesting that having a multiparametric MRI (mpMRI) scan could really help to decide which men needed a prostate biopsy because they really did or didn’t have prostate cancer. … READ MORE …

New consensus statement on monitoring for prostate cancer risk after a first, negative biopsy

There has been no really clear and formal guidance available on how to monitor patients for risk of prostate cancer after a first, negative, standard, 12-core, systematic biopsy. New guidance from the American Urological Association (AUA) and the Society of Abdominal Radiology (SAR) may be helpful in addressing this situation. … READ MORE …